The University of Chicago Header Logo

Olwen Hahn

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Rimawi MF, Weiss A, Winer EP, Hunt KK, Perou CM, Ellis MJ, Partridge AH, Carey LA. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371. PMID: 38236590; PMCID: PMC10797521.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, Nanda R, Jaskowiak NT, Fleming GF, Olopade OI, Pearson AT, Huo D, Howard FM. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220. PMID: 38146744; PMCID: PMC10948297.
      Citations:    Fields:    Translation:Humans
    3. Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Chen N, Hahn O, Fleming G, Huo D, Nanda R. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83. PMID: 37120458; PMCID: PMC10224832.
      Citations: 3     Fields:    Translation:Humans
    4. Vayani OR, Asif H, Klein A, Hahn OM, Pearson AT, Arora VM, Olopade OI, Golden DW. Adapting a Medical School Cancer Research Education Program to the Virtual Environment: a Mixed-Methods Study. J Cancer Educ. 2023 10; 38(5):1501-1508. PMID: 37058222; PMCID: PMC10102672.
      Citations:    Fields:    Translation:HumansPHPublic Health
    5. Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510. PMID: 36821125; PMCID: PMC9951099.
      Citations: 26     Fields:    Translation:Humans
    6. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362. PMID: 36996380; PMCID: PMC10414728.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    7. Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). J Clin Oncol. 2023 06 10; 41(17):3184-3193. PMID: 36977292; PMCID: PMC10256355.
      Citations: 10     Fields:    Translation:Humans
    8. Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Chen N, Hahn O, Fleming G, Huo D, Nanda R. The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer. Res Sq. 2023 Mar 16. PMID: 36993723; PMCID: PMC10055663.
    9. Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ, Small EJ, Morris MJ, Naughton MJ, Pierce JP, Marshall J. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). Eur Urol Focus. 2022 11; 8(6):1607-1616. PMID: 35504836; PMCID: PMC10365132.
      Citations: 1     Fields:    Translation:Humans
    10. Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334. PMID: 35044810; PMCID: PMC9015203.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    11. Gnant M, Dueck AC, Frantal S, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Haddad TC, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL, PALLAS groups and investigators, Martin M, Hernando Fernández de Aránguiz B, Perelló A, Schurmans C. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 01 20; 40(3):282-293. PMID: 34874182; PMCID: PMC10476784.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    12. Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278. PMID: 34716198; PMCID: PMC8776596.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    13. Boughey JC, Snyder RA, Kantor O, Zheng L, Chawla A, Nguyen TT, Hillman SL, Hahn OM, Mandrekar SJ, Roland CL. Impact of the COVID-19 Pandemic on Cancer Clinical Trials. Ann Surg Oncol. 2021 Nov; 28(12):7311-7316. PMID: 34236550; PMCID: PMC8265286.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic Health
    14. Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K, Curtit E, Muñoz-Mateu M. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021 08; 153:223-233. PMID: 34214937.
      Citations: 6     Fields:    Translation:Humans
    15. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    16. Lynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 2021 10 01; 127(19):3622-3630. PMID: 34157782.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    17. Hong D, Das LC, Daily E, Levine SK, Hahn OM, Liauw SL, Golden DW, Son CH. Goals of care discussions: perceptions of radiation and medical oncologists. Support Care Cancer. 2021 Dec; 29(12):7279-7288. PMID: 34031753.
      Citations: 2     Fields:    Translation:Humans
    18. Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496. PMID: 33989025; PMCID: PMC8462587.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    19. Eastham JA, Heller G, Hillman DW, Hahn OM, Parsons JK, Mohler JL, Small EJ, Morris M. Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). J Urol. 2021 Aug; 206(2):319-324. PMID: 33780276; PMCID: PMC8273099.
      Citations: 2     Fields:    Translation:Humans
    20. Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193. PMID: 33095682; PMCID: PMC7723687.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    21. Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. PMID: 32706639; PMCID: PMC7479762.
      Citations: 32     Fields:    Translation:Humans
    22. O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC). Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. PMID: 32378051.
      Citations: 6     Fields:    Translation:Humans
    23. Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):140-148. PMID: 31935026; PMCID: PMC6990696.
      Citations: 23     Fields:    Translation:HumansAnimals
    24. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501. PMID: 31399500; PMCID: PMC6853096.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    25. Loibl S, Hyslop T, Aktas B, Cirrincione CT, Mehta K, Barry WT, Carey LA, Partridge A, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN, GEICAM Spanish Breast Cancer Group, GBG (German Breast Group), Alliance for Clinical Trials in Oncology (Alliance), Martín M, De la Haba-Rodríguez J, Morales S, Garcia-Saenz JA, Martinez-Jañez N. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98. PMID: 31276981; PMCID: PMC6718694.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    26. McKillip RP, Hahn OM, Bartkowiak B, Rosenberg CA, Olopade OI, Arora VM, Golden DW. Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. J Cancer Educ. 2019 02; 34(1):50-55. PMID: 28831669; PMCID: PMC5823720.
      Citations: 6     Fields:    Translation:Humans
    27. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]. Eur J Cancer. 2018 11; 103:287. PMID: 30270112; PMCID: PMC6299293.
      Citations: 4     Fields:    
    28. Akthar AS, Hellekson CD, Ganai S, Hahn OM, Maggiore RJ, Cohen EE, Posner MC, Chmura SJ, Howard AR, Golden DW. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626. PMID: 27873183.
      Citations: 9     Fields:    Translation:Humans
    29. Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat. 2018 Sep; 171(2):325-334. PMID: 29789969; PMCID: PMC6076849.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    30. Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun. 2018 Jun; 10:190-192. PMID: 30009277; PMCID: PMC6042467.
      Citations: 3     
    31. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125. PMID: 29550566; PMCID: PMC6057479.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    32. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185. PMID: 29487024; PMCID: PMC6173195.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    33. Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017; 3:37. PMID: 28948213; PMCID: PMC5608692.
      Citations: 53     
    34. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int. 2018 04; 121(4):534-539. PMID: 28437029; PMCID: PMC5654696.
      Citations: 10     Fields:    Translation:HumansAnimalsCTClinical Trials
    35. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE, Alliance for Clinical Trials in Oncology. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192. PMID: 28489511; PMCID: PMC5493050.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    36. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Sachdev T, Gajra A, Bertino EM, Reckamp KL, Molina J, Schiller J, Mitchell-Edwards K, Friedman P, Ritter J, Milne G, Stinchcombe TE, Hahn O, Vokes EE. Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220-221. PMID: 28586968.
    37. Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 05; 12(5):843-849. PMID: 28161554; PMCID: PMC5500219.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    38. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 02 20; 35(6):591-597. PMID: 28199818; PMCID: PMC5455807.
      Citations: 273     Fields:    Translation:HumansCTClinical Trials
    39. Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911. PMID: 27601514; PMCID: PMC5063186.
      Citations: 8     Fields:    Translation:Humans
    40. Oskvarek J, Braunstein S, Farnan J, Ferguson MK, Hahn O, Henderson T, Hong S, Levine S, Rosenberg CA, Golden DW. Medical Student Knowledge of Oncology and Related Disciplines: a Targeted Needs Assessment. J Cancer Educ. 2016 09; 31(3):529-32. PMID: 26153490; PMCID: PMC4706503.
      Citations: 19     Fields:    Translation:Humans
    41. Drazer MW, Salama JK, Hahn OM, Weichselbaum RR, Chmura SJ. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32. PMID: 27078719.
      Citations: 1     Fields:    Translation:Humans
    42. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9. PMID: 27138575; PMCID: PMC5012690.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    43. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 01; 33(1):13-21. PMID: 25092775; PMCID: PMC4268249.
      Citations: 389     Fields:    Translation:HumansCTClinical Trials
    44. Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK, Ranck MC. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95. PMID: 22868242.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    45. Hahn OM, Schilsky RL. Randomized controlled trials and comparative effectiveness research. J Clin Oncol. 2012 Dec 01; 30(34):4194-201. PMID: 23071239.
      Citations: 12     Fields:    Translation:Humans
    46. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63. PMID: 22245973; PMCID: PMC3658119.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    47. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WM. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4. PMID: 20395787; PMCID: PMC4644601.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    48. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8. PMID: 18824708; PMCID: PMC2736992.
      Citations: 97     Fields:    Translation:Humans
    49. Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42. PMID: 18045058.
      Citations: 3     Fields:    Translation:HumansCells
    50. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21. PMID: 16988583.
      Citations: 20     Fields:    Translation:Humans
    51. Hahn O, Salgia R. Novel therapies in lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):343-67, vii. PMID: 15833410.
      Citations: 2     Fields:    Translation:Humans
    Hahn's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (193)
    Co-Authors (49)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors